79 related articles for article (PubMed ID: 17694780)
1. Immune-boosting prostate cancer vaccine endorsed by FDA advisors.
McBride D
ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780
[No Abstract] [Full Text] [Related]
2. Concerns about Provenge simmer as CMS ponders coverage.
Goozner M
J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
[No Abstract] [Full Text] [Related]
3. The regulator disapproves.
Nat Biotechnol; 2008 Jan; 26(1):1. PubMed ID: 18182998
[No Abstract] [Full Text] [Related]
4. Fallout from flip-flops.
Froese P
Nat Biotechnol; 2008 Jun; 26(6):614-5. PubMed ID: 18536677
[No Abstract] [Full Text] [Related]
5. Cellular immunotherapy licensed for advanced prostate cancer.
Traynor K
Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
[No Abstract] [Full Text] [Related]
6. The Provenge decision.
DeVita VT
Nat Clin Pract Oncol; 2007 Jul; 4(7):381. PubMed ID: 17554239
[No Abstract] [Full Text] [Related]
7. Dendritic cell vaccine hits FDA roadblock.
Morrow T
Manag Care; 2007 Jun; 16(6):52-3. PubMed ID: 17682740
[No Abstract] [Full Text] [Related]
8. Consultation corner. Prostate cancer vaccine offers new direction.
Drake C
Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):6-7. PubMed ID: 20848753
[No Abstract] [Full Text] [Related]
9. A prostate cancer 'vaccine' under development.
Mayo Clin Health Lett; 2009 Dec; 27(12):4. PubMed ID: 20082492
[No Abstract] [Full Text] [Related]
10. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
Chambers JD; Neumann PJ
N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
[No Abstract] [Full Text] [Related]
11. Name that prostate cancer drug.
Gomella LG
Can J Urol; 2011 Jun; 18(3):5666. PubMed ID: 21703036
[No Abstract] [Full Text] [Related]
12. Landmark approval for Dendreon's cancer vaccine.
DeFrancesco L
Nat Biotechnol; 2010 Jun; 28(6):531-2. PubMed ID: 20531312
[No Abstract] [Full Text] [Related]
13. Vaccine approved for prostate cancer. The vaccine, which harnesses the immune system, may provide more treatment options for all cancers.
Duke Med Health News; 2010 Jul; 16(7):3. PubMed ID: 20662142
[No Abstract] [Full Text] [Related]
14. Abigail Alliance v. Von Eschenbach: restricting access to potentially lifesaving drugs singe 2007.
Goodman AJ
J Contemp Health Law Policy; 2008; 25(1):107-41. PubMed ID: 19137749
[No Abstract] [Full Text] [Related]
15. Approval of provenge seen as first step for cancer treatment vaccines.
Brower V
J Natl Cancer Inst; 2010 Aug; 102(15):1108-10. PubMed ID: 20668267
[No Abstract] [Full Text] [Related]
16. FDA approves prostate cancer "vaccine".
Tanne JH
BMJ; 2010 May; 340():c2431. PubMed ID: 20442242
[No Abstract] [Full Text] [Related]
17. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer?
Moyad MA
Urol Nurs; 2007 Jun; 27(3):256-7. PubMed ID: 17674606
[TBL] [Abstract][Full Text] [Related]
18. Cancer vaccine approval could open floodgates.
Nat Med; 2010 Jun; 16(6):615. PubMed ID: 20526296
[No Abstract] [Full Text] [Related]
19. Is Provenge Angst a symbol or symptom of the times?
Holcombe DG
Am J Manag Care; 2012 May; 18(3 Spec No.):SP108-9. PubMed ID: 22642274
[No Abstract] [Full Text] [Related]
20. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.
Madan RA; Gulley JL
Expert Rev Vaccines; 2011 Feb; 10(2):141-50. PubMed ID: 21332262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
